Premium
Neuroprotection in glaucoma: recent advances and clinical translation
Author(s) -
Guymer Chelsea,
Wood John PM,
Chidlow Glyn,
Casson Robert J
Publication year - 2018
Publication title -
clinical and experimental ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.3
H-Index - 74
eISSN - 1442-9071
pISSN - 1442-6404
DOI - 10.1111/ceo.13336
Subject(s) - neuroprotection , medicine , glaucoma , neurodegeneration , intraocular pressure , neuroscience , intensive care medicine , ophthalmology , pharmacology , pathology , disease , biology
Intraocular pressure (IOP) reduction is currently the only evidence‐based treatment strategy for glaucoma. However, IOP control in some individuals is challenging. Despite optimal treatment, a significant proportion of individuals will progress, with loss of visual field, loss of driving vision and impaired quality of life. A new modality that could augment current treatment and reduce the rate of neurodegeneration to preserve vision throughout life would be a major breakthrough. A vast number of studies have reported effective neuroprotection in animal models of glaucoma; however, translation to the clinic remains a major hurdle. Herein, we explore the therapeutic advancements in non‐IOP‐dependent neuroprotection research based upon potential pathogenic mechanisms and propose strategies to improve the clinical translation of neuroprotective research in glaucoma.